19.85
price up icon7.30%   1.35
pre-market  Vorhandelsmarkt:  19.78   -0.07   -0.35%
loading

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Mar 25, 2026

Ultragenyx Pharmaceutical Stock Hits Day Low of $18.29 Amid Price Pressure - Markets Mojo

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Pharmaceutical Hits Day Low at $19.86 Amid Price Pressure - Markets Mojo

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo

Mar 25, 2026
pulisher
Mar 25, 2026

Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class A - GuruFocus

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.

Mar 25, 2026
pulisher
Mar 25, 2026

RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Ro - pharmiweb.com

Mar 25, 2026
pulisher
Mar 25, 2026

Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: - GlobeNewswire

Mar 25, 2026
pulisher
Mar 25, 2026

RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - The AI Journal

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa - TipRanks

Mar 25, 2026
pulisher
Mar 25, 2026

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

Mar 25, 2026
pulisher
Mar 25, 2026

Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar

Mar 25, 2026
pulisher
Mar 25, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN

Mar 25, 2026
pulisher
Mar 25, 2026

Momentum Shift: Will Ultragenyx Pharmaceutical Inc outperform tech stocksGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 25, 2026

Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results - simplywall.st

Mar 25, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs Downgrades Ultragenyx (RARE), Slashes Price Target by 59% | RARE Stock News - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral By Investing.com - Investing.com India

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs Downgrades Ultragenyx (RARE) Following Trial Setba - GuruFocus

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low After Analyst Downgrade - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - Seeking Alpha

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx stock hits 52-week low at 18.36 USD - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by The Goldman Sachs Group - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral From Buy, Adjusts PT to $25 From $61 - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral - Investing.com UK

Mar 24, 2026
pulisher
Mar 24, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investor Alert: Deadline in Lawsuit on April 6, 2026 - openPR.com

Mar 24, 2026
pulisher
Mar 23, 2026

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire

Mar 23, 2026
pulisher
Mar 23, 2026

RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire

Mar 23, 2026
pulisher
Mar 23, 2026

RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm

Mar 23, 2026
pulisher
Mar 22, 2026

WOODSTOCK CORP's Ultragenyx Pharmaceutical Inc(RARE) Holding History - GuruFocus

Mar 22, 2026
pulisher
Mar 22, 2026

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire

Mar 22, 2026
pulisher
Mar 22, 2026

2026-03-22 | RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse

Mar 22, 2026
pulisher
Mar 21, 2026

Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 47% One-Year Share Price Fall - Sahm

Mar 21, 2026
pulisher
Mar 21, 2026

RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record

Mar 21, 2026
pulisher
Mar 21, 2026

RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Mar 21, 2026
pulisher
Mar 20, 2026

How Ultragenyx Pharmaceutical Inc. (RARE) Affects Rotational Strategy Timing - Stock Traders Daily

Mar 20, 2026
pulisher
Mar 20, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 20, 2026
pulisher
Mar 20, 2026

Two new Ultragenyx hires get 10,839 stock units under Nasdaq rule - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

A Look At Ultragenyx Pharmaceutical’s Valuation After Recent Share Price Weakness - Yahoo Finance

Mar 20, 2026
pulisher
Mar 20, 2026

Mucopolysaccharidosis Treatment Market to Reach US$6.76 - openPR.com

Mar 20, 2026
pulisher
Mar 20, 2026

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - Lelezard

Mar 20, 2026
pulisher
Mar 20, 2026

RARE Stock Price, Quote & Chart | ULTRAGENYX PHARMACEUTICAL IN (NASDAQ:RARE) - ChartMill

Mar 20, 2026
pulisher
Mar 19, 2026

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - ChartMill

Mar 19, 2026
pulisher
Mar 19, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire

Mar 19, 2026
pulisher
Mar 18, 2026

RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record

Mar 18, 2026
pulisher
Mar 18, 2026

RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire

Mar 18, 2026
pulisher
Mar 18, 2026

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph

Mar 18, 2026
pulisher
Mar 18, 2026

LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION (2026-03-18) - Seeking Alpha

Mar 18, 2026
pulisher
Mar 18, 2026

LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION - Sahm

Mar 18, 2026
pulisher
Mar 17, 2026

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors - GlobeNewswire

Mar 17, 2026
pulisher
Mar 17, 2026

DTX301 Gene Therapy Lowers Ammonia Levels in Ornithine Transcarbamylase Deficiency at 36 Weeks - Neurology Live

Mar 17, 2026
pulisher
Mar 17, 2026

RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire

Mar 17, 2026
pulisher
Mar 17, 2026

Aquatic Capital Management LLC Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Mar 17, 2026
pulisher
Mar 17, 2026

Phase 3 DTX301 Gene Therapy Data Could Be A Game Changer For Ultragenyx Pharmaceutical (RARE) - Sahm

Mar 17, 2026
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
Kapitalisierung:     |  Volumen (24h):